Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001165" target="_blank" >RIV/00064190:_____/23:10001165 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10466005

Výsledek na webu

<a href="https://link.springer.com/article/10.1007/s40292-023-00582-5" target="_blank" >https://link.springer.com/article/10.1007/s40292-023-00582-5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40292-023-00582-5" target="_blank" >10.1007/s40292-023-00582-5</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Popis výsledku v původním jazyce

Hypertensive disorders in pregnancy are associated with increased risk of maternal, fetal, and neonatal morbidity and mortality. It is important to distinguish between pre-existing (chronic) hypertension and gestational hypertension, developing after 20 weeks of gestation and usually resolving within 6 weeks postpartum. There is a consensus that systolic blood pressure GREATER-THAN OR EQUAL TO 170 or diastolic blood pressure GREATER-THAN OR EQUAL TO 110 mmHg is an emergency and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. The current European guidelines recommend initiating drug treatment in pregnant women with persistent elevation of blood pressure GREATER-THAN OR EQUAL TO 150/95 mmHg and at values &gt; 140/90 mmHg in women with gestational hypertension (with or without proteinuria), with pre-existing hypertension with the superimposition of gestational hypertension, and with hypertension with subclinical organ damage or symptoms at any time during pregnancy. Methyldopa, labetalol, and calcium antagonists (the most data are available for nifedipine) are the drugs of choice. The results of the CHIPS and CHAP studies are likely to reduce the threshold for initiating treatment. Women with a history of hypertensive disorders in pregnancy, particularly those with pre-eclampsia, are at high risk of developing cardiovascular disease later in life. Obstetric history should become a part of the cardiovascular risk assessment in women. (C) 2023, The Author(s).

Název v anglickém jazyce

Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview

Popis výsledku anglicky

Hypertensive disorders in pregnancy are associated with increased risk of maternal, fetal, and neonatal morbidity and mortality. It is important to distinguish between pre-existing (chronic) hypertension and gestational hypertension, developing after 20 weeks of gestation and usually resolving within 6 weeks postpartum. There is a consensus that systolic blood pressure GREATER-THAN OR EQUAL TO 170 or diastolic blood pressure GREATER-THAN OR EQUAL TO 110 mmHg is an emergency and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. The current European guidelines recommend initiating drug treatment in pregnant women with persistent elevation of blood pressure GREATER-THAN OR EQUAL TO 150/95 mmHg and at values &gt; 140/90 mmHg in women with gestational hypertension (with or without proteinuria), with pre-existing hypertension with the superimposition of gestational hypertension, and with hypertension with subclinical organ damage or symptoms at any time during pregnancy. Methyldopa, labetalol, and calcium antagonists (the most data are available for nifedipine) are the drugs of choice. The results of the CHIPS and CHAP studies are likely to reduce the threshold for initiating treatment. Women with a history of hypertensive disorders in pregnancy, particularly those with pre-eclampsia, are at high risk of developing cardiovascular disease later in life. Obstetric history should become a part of the cardiovascular risk assessment in women. (C) 2023, The Author(s).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

High Blood Pressure and Cardiovascular Prevention

ISSN

1120-9879

e-ISSN

1179-1985

Svazek periodika

30

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

15

Strana od-do

289-303

Kód UT WoS článku

001004835200001

EID výsledku v databázi Scopus

2-s2.0-85161665253